
## WHAT IS CLAIMED IS:

- 1. A magnetic resonance contrast agent comprising:
- 2 a tetraazacyclododecane ligand having a general structural
- 3 formula as follows:



4

and comprising a macrocyclic ring and wherein pendant arms 5 R, R', R'' and R''' attached to a ring nitrogen have the general 6 formula: -C'HR1R2 and for three or more of said pendant arms a 7 chirality of said carbon atoms C' are identical for each of said 8 three or more pendant arms, said R1 are groups larger than 9 hydrogen, and said R<sup>2</sup> is selected from the group consisting of: 10 an alcohol (-CH<sub>2</sub>OH); 11 amides (-CONR<sup>3</sup>R<sup>4</sup>, where R<sup>3</sup> and R<sup>4</sup> are organic groups); 12 a carboxylate (-COOH); 13


- phosphinates (-PO<sub>2</sub>HR<sup>5</sup>, where R<sup>5</sup> is an organic group);
- 15 and
- a phosphonate  $(-PO(OH)_2)$ ; and
- wherein one or more of substituents R<sup>6</sup> is a group larger
- than a methyl group and is located on one or more ring carbons;
- 19 and
- 20 a paramagnetic metal ion coordinated to said
- 21 tetraazacyclododecane ligand.
  - 2. The magnetic resonance contrast agent as recited
  - 2 in Claim 1, wherein said chirality of said carbon atoms C'
  - 3 provides said three or more of said pendant arms with a  $\Lambda$  or
  - 4  $\Delta$  orientation, and wherein a chirality of a ring carbon bonded to
  - 5 said one or more of substituents R<sup>6</sup> provides said macrocyclic
  - 6 ring with an identical orientation,  $\lambda\lambda\lambda\lambda$  or  $\delta\delta\delta\delta$ , respectively,
  - 7 said tetraazacyclododecane ligand thereby having a monocapped
  - 8 twisted square antiprism coordination geometry.
  - 3. The magnetic resonance contrast agent as recited
  - 2 in Claim 2, wherein said R<sup>2</sup> group is said alcohol or amide, and
  - 3 further including a water molecule associated with said
  - 4 tetraazacyclododecane ligand and said paramagnetic metal ion,
  - 5 said water molecule having a residence lifetime at about 298°K,

- 6  $\tau_{M}^{298}$ , of between about 1 and about 100 microseconds.
- 4. The magnetic resonance contrast agent as recited
- 2 in Claim 2, wherein said  $R^2$  group is said carboxylate, and
- 3 further including a water molecule associated with said
- 4 tetraazacyclododecane ligand and said paramagnetic metal ion,
- 5 said water molecule having a residence lifetime at about 298°K,
- 6  $\tau_{M}^{298}$ , of between about 10 and about 100 nanoseconds.
- 5. The magnetic resonance contrast agent as recited
- in Claim 1, wherein said chirality of said carbon atoms C'
- 3 is controlled to provide said three or more of said pendant arms
- 4 with a  $\Delta$  or  $\Lambda$  orientation, and wherein a chirality of a ring
- 5 carbon bonded to said one or more of substituents R<sup>6</sup> provides
- 6 said macrocyclic ring with an opposite orientation,  $\lambda\lambda\lambda\lambda$  or  $\delta\delta\delta\delta$ ,
- 7 respectively, said tetraazacyclododecane ligand thereby having a
- 8 monocapped square antiprism coordination geometry.
- 6. The magnetic resonance contrast agent as recited
- 2 in Claim 5, wherein said R<sup>2</sup> group is said alcohol or amide, and
- 3 further including a water molecule associated with said
- 4 tetraazacyclododecane ligand and said paramagnetic metal ion,
- 5 said water molecule having a residence lifetime at about 298°K,

- 6  $\tau_{\rm M}^{298}$ , of between about 10 and about 5000 microseconds.
- 7. The magnetic resonance contrast agent as recited
- 2 in Claim 5, wherein said R<sup>2</sup> group is said carboxylate, and
- 3 further including a water molecule associated with said
- 4 tetraazacyclododecane ligand and said paramagnetic metal ion,
- 5 said water molecule having a residence lifetime at about 298°K,
- 6  $\tau_{\rm M}^{298}$ , of between about 100 and about 500 nanoseconds.
- 8. The magnetic resonance contrast agent as recited
- 2 in Claim 5, wherein said R<sup>2</sup> group is said phosphonate or said
- 3 phosphinate, and further including a water molecule associated
- 4 with said tetraazacyclododecane ligand and said paramagnetic
- 5 metal ion, said water molecule having a residence lifetime at
- 6 about 298°K,  $\tau_M^{298}$ , of between about 10 and about 100 nanoseconds.
- 9. The magnetic resonance contrast agent as recited
- 2 in Claim 1, wherein said  $R^1$  is a methyl group, said  $R^2$  is said
- 3 carboxylate, and said  $R^6$  is a para-aminobenzyl group and said
- 4 paramagnetic metal ion is Gd<sup>3+</sup>.
  - 10. The magnetic resonance contrast agent as recited
- in Claim 10, further including a water molecule associated

- 3 with said tetraazacyclododecane ligand said water molecule
- 4 having residence lifetime at about 298°K,  $\tau_M^{298}$ , of about 15
- 5 nanoseconds.
- 11. The magnetic resonance contrast agent as recited
- 2 in Claim 1, wherein at least one of said one or more of
- 3 substituents R<sup>6</sup> include a functional group selected from the
- 4 group consisting of:
- 5 amino groups;
- 6 carboxylates;
- 7 isothiocyanates; and
- 8 maleiimdes; and
- 9 a carrier component conjugated to said functional group.
- 12. The magnetic resonance contrast agent as recited in Claim 1, wherein said paramagnetic metal is a lanthanide ion.

- 13. A method of using a magnetic resonance contrast agent, comprising:
- 3 subjecting a contrast agent contained within a sample to a
- 4 radio frequency pulse wherein said contrast agent is a
- 5 tetraazacyclododecane ligand having a general formula of:



7 and comprising a macrocyclic ring and wherein pendant arms R,

R', R'' and R''' attached to a ring nitrogen have the general

9 formula:  $-C'HR^1R^2$  and for three or more of said pendant arms a

10 chirality of said carbon atoms C' are identical for each of said

11 three or more pendant arms, said R<sup>1</sup> are groups larger than

hydrogen, and said R<sup>2</sup> is selected from the group consisting of:

an alcohol (-CH<sub>2</sub>OH);

2

6

8

12

amides  $(-CONR^3R^4$ , where  $R^3$  and  $R^4$  are organic groups);

a carboxylate (-COOH);

phosphinates (-PO<sub>2</sub>HR<sup>5</sup>, where R<sup>5</sup> is an organic group);

17 and

18 a phosphonate  $(-PO(OH)_2)$ ; and

- 19 wherein one or more of substituents R<sup>6</sup> is a group larger than a
- 20 methyl group and is located on one or more ring carbons; and
- 21 wherein said tetraazacyclododecane ligand further includes a
- 22 paramagnetic metal ion (M3+) coordinated to said
- 23 tetraazacyclododecane ligand and a water molecule  $(H_2O)$
- 24 associated with said tetraazacyclododecane ligand; and
- obtaining a magnetic resonance signal by applying a radio
- 26 frequency pulse at about a resonance frequency of water.
  - 14. The method as recited in Claim 13, further includes
  - 2 producing a magnetic resonance image from said magnetic
  - 3 resonance signal.
  - 15. The method as recited in Claim 13, wherein said
  - 2 contrast agent further includes a carrier component conjugated
  - 3 to said one or more of substituents  $R^6$ .
- 16. The method as recited in Claim 15, wherein
- said water molecule has a relaxivity at 298°C,  $r_1^{298}$ , of at least
- 3 about 50  $\text{mM}^{-1} \text{ s}^{-1}$ .


## 17. A magnetic resonance system, comprising:

a magnetic resonance contrast agent, wherein said magnetic

3 resonance contrast agent includes a tetraazacyclododecane

4 ligand, having a general formula of:

5



and comprising a macrocyclic ring and wherein pendant arms R, 6 R', R'' and R''' attached to a ring nitrogen have the general 7 formula: -C'HR1R2 and for three or more of said pendant arms a 8 chirality of said carbon atoms C' are identical for each of said 9 three or more pendant arms, said R1 are groups larger than 10 hydrogen, and said R<sup>2</sup> is selected from the group consisting of: 11 12 an alcohol (-CH<sub>2</sub>OH); amides (-CONR<sup>3</sup>R<sup>4</sup>, where R<sup>3</sup> and R<sup>4</sup> are organic groups); 13 a carboxylate (-COOH); 14

phosphinates (-PO<sub>2</sub>HR<sup>5</sup>, where R<sup>5</sup> is an organic group);

16 and

25

2

a phosphonate  $(-PO(OH)_2)$ ; and

wherein one or more of substituents R<sup>6</sup> is a group larger 18 than a methyl group and is located on one or more ring carbons; 19 and wherein said tetraazacyclododecane ligand further includes a 20  $(M^{3+})$ metal ion coordinated said 21 paramagnetic to molecule water tetraazacyclododecane ligand and  $(H_2O)$ 22 a associated with said tetraazacyclododecane ligand, wherein said 23 magnetic resonance contrast agent produces a magnetic resonance 24

a magnetic resonance apparatus configured to produce said radio-frequency pulse.

signal when subjected to a radio-frequency pulse; and

- 18. The magnetic resonance system recited in Claim 17,
- 2 further comprising a sample that is a is a living subject and
- 3 said sample contains said magnetic resonance contrast agent.
  - 19. The magnetic resonance system recited in Claim 17,
- 2 wherein said magnetic resonance apparatus produces a image of
- 3 said sample from said magnetic resonance signal.
- 20. The magnetic resonance system recited in Claim 17, wherein said magnetic resonance contrast agent further includes

- a carrier component conjugated to said one or more of
- 4 substituents  $R^6$  and said water molecule has a relaxivity at
- 5 298°C,  $r_1^{298}$ , of at least about 50 mM<sup>-1</sup> s<sup>-1</sup>.